siRNA Conjugates Market, By Therapeutic Area (Rare Disease, Oncology, Chronic Disease, Central Nervous System, and Cardiovascular), By Development Stage, By Conjugate Type, By End User, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
|
Report ID
AV5079
|
Published Date
April 2026
|
Pages
351
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
siRNA Conjugates Market size was valued at US$ 810.71 Million in 2025, expanding at a CAGR of 15.10% from 2026 to 2033.
siRNA conjugates are advanced therapeutic agents in which small interfering RNA (siRNA) is chemically linked to delivery-enhancing molecules. This modification improves stability, enables targeted delivery into cells, and enhances cellular uptake. By selectively silencing specific genes, these therapies offer a promising approach for treating a range of diseases with greater precision and fewer side effects.
The siRNA conjugates market is expanding rapidly, driven by advancements in delivery technologies, increasing research in RNA-based therapeutics, and growing investment in precision medicine. These conjugates enable highly targeted gene silencing by delivering siRNA directly to specific cells, improving therapeutic accuracy and safety while reducing off-target effects and associated side effects. In 2025, Alnylam Pharmaceuticals announced a significant expansion of its U.S. manufacturing capabilities with a $250 million investment dedicated to siRNA drug production. This initiative aims to enhance the speed, scale, and precision of RNAi therapeutic development and delivery, reflecting rising demand for targeted gene-silencing treatments. Overall, these developments highlight the increasing adoption of siRNA conjugates as a key component of next-generation precision medicine.
siRNA Conjugates Market- Market Dynamics
Growing Awareness of Targeted Therapies Driving Market Demand
One of the key drivers of the increasing demand for targeted therapies is the growing adoption of advanced drug delivery platforms, precision medicine approaches, and next-generation biologics such as siRNA conjugates and antibody-drug conjugates. Recent advancements also include targeted small-molecule inhibitors, novel immune checkpoint therapies, antibody-drug conjugates, and the use of AI-powered tools to accelerate drug discovery and development. These innovations are focused on improving treatment precision, minimizing side effects, and enhancing overall patient outcomes, thereby supporting the evolution of a more advanced, technology-driven healthcare ecosystem.
In late 2025 and early 2026, Alnylam Pharmaceuticals continued to advance its RNAi therapeutic pipeline, reporting strong product revenue growth for 2025 and outlining its 2026 development strategy. This includes multiple planned clinical readouts and the initiation of new studies aimed at expanding its RNA interference-based treatments for genetic and other diseases. Overall, these developments highlight the expanding role of siRNA conjugates in precision medicine, driven by ongoing innovation, clinical progress, and the demand for safer and more effective targeted therapies.
siRNA Conjugates Market- Segmentation Analysis:
The Global siRNA Conjugates Market is segmented on the basis of Therapeutic Area, Development Stage, Conjugate Type, End User, and Region.
The cardiovascular, central nervous system (CNS), chronic disease, oncology, and rare disease segments represent major application areas in the siRNA conjugates market, as these therapies enable precise gene silencing in complex and hard-to-treat conditions. Increasing research and development activities, along with the rising demand for highly targeted treatment approaches, are driving market growth in these therapeutic areas. For instance, a 2023 review by the U.S. National Institutes of Health (NIH) on the global cell and gene therapy landscape reported that more than 100 advanced gene, cell, and RNA therapy products had been approved worldwide. In addition, over 3,700 therapies were in clinical and preclinical development, reflecting a substantial expansion in innovative treatment pipelines compared to previous years. The review further noted that the global pipeline included thousands of candidates across gene, cell, and RNA-based modalities, highlighting the rapid evolution of advanced therapeutics, including siRNA conjugates, within precision medicine.
From an end-user perspective, hospitals, research institutes, and specialty clinics play a vital role in the siRNA conjugates market due to their capabilities in patient care, clinical trials, and advanced therapeutic development. Hospitals support the broad clinical application and administration of RNA-based therapies, while research institutes focus on discovery, development, and optimization of novel siRNA conjugates. For example, according to the European Commission, there were approximately 2.3 million hospital beds available across the European Union in 2023, averaging around 511 beds per 100,000 inhabitants. Between 2013 and 2023, the total number of hospital beds in the EU declined by about 7%, although some countries, including Portugal, Spain, and Romania, recorded slight increases on a per-capita basis. These trends underscore the importance of robust healthcare infrastructure in supporting the development and delivery of siRNA conjugate-based therapies.
siRNA Conjugates Market- Geographical Insights
The siRNA conjugates market is segmented by region into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America holds a leading position in the market, driven by its advanced healthcare infrastructure, strong research capabilities, and high adoption of precision medicine. The region also benefits from increasing demand for targeted therapies, substantial investment in RNA-based treatments, and supportive regulatory frameworks that encourage innovation. For example, in June 2025, U.S. government data indicated that more than 120 global clinical trials of RNA cancer vaccines were underway across indications such as melanoma, pancreatic, brain, lung, and breast cancers, reflecting heightened research activity in RNA-based therapeutics. By mid-2025, RNA cancer vaccine studies reported promising outcomes, including up to a 44% reduction in melanoma recurrence along with strong immune responses in other cancer types. These advancements highlight North America’s leadership in the siRNA conjugates market, supported by strong infrastructure, active clinical research, and significant progress in RNA-based therapies.
The Asia-Pacific region is also experiencing rapid growth, supported by rising healthcare expenditure and increasing awareness of advanced therapeutic approaches. For instance, according to IBEF, India’s healthcare sector was valued at approximately US$372 billion in 2023, reflecting strong growth supported by both public and private investment. The same source notes that by 2024–25, India’s healthcare workforce exceeded 6 million professionals, while the government allocated around Rs. 99,858 crore (US$11.50 billion) to the sector in the Union Budget 2025–26. Overall, these developments underscore the Asia-Pacific region’s expanding role in healthcare advancement and the growing adoption of innovative therapies, driven by sustained investment, infrastructure development, and workforce expansion.
Europe siRNA Conjugates Market- Country Insights
Europe is strengthening its position in the siRNA conjugates market, supported by collaborative research initiatives, harmonized regulatory frameworks, and a strong focus on RNA-based therapeutic innovation. For instance, in April 2024, Wave Life Sciences Ltd. advanced its RNA medicines platform with multiple siRNA and RNA editing programs. This included the progression of its GalNAc-conjugated INHBE siRNA (WVE-007) into clinical development, as well as the expansion of clinical trials for its RNA editing candidate (WVE-006) for alpha-1 antitrypsin deficiency. These developments highlight increasing innovation and clinical momentum in RNA-based therapeutics. Overall, these advancements reflect Europe’s growing leadership in siRNA therapeutics, driven by sustained innovation, active clinical research, and strong cross-border collaboration.
siRNA Conjugates Market- Competitive Landscape:
The siRNA conjugates market is highly competitive, with leading companies such as Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Silence Therapeutics, Dicerna Pharmaceuticals, Wave Life Sciences, Sirnaomics, Inc., and Quark Pharmaceuticals, Inc. driving innovation in targeted RNA-based therapies. These players are focused on improving precision delivery systems, enhancing therapeutic efficacy, and minimizing off-target effects across a wide range of disease areas. Ongoing investments in partnerships, research and development, and clinical trials are helping expand product pipelines and accelerate the advancement of next-generation siRNA technologies.
In August 2024, Sirnaomics, Inc. formed a strategic partnership with Gore Range Capital LLC to establish Sagesse Bio, Inc., a joint venture aimed at expanding RNAi therapeutics into aesthetic medicine. This collaboration focuses on accelerating the clinical development of lead siRNA candidates for applications such as body contouring and focal fat reduction, reflecting efforts to broaden the use of RNA-based innovations into new therapeutic fields.
Recent Developments
- In 2025, Arrowhead Pharmaceuticals announced FDA approval and the commercial launch of REDEMPLO® (plozasiran), its first marketed siRNA therapeutic for adults with familial chylomicronemia syndrome. This milestone marks the company’s transition from development to commercial-stage RNAi therapeutics.
- In June 2025, Sinopep-Allsino Biopharmaceutical Co., Ltd. entered into a strategic cooperation agreement with Vazyme, forming a joint venture to advance synthetic biology platforms and strengthen biopharmaceutical technology capabilities.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL SIRNA CONJUGATES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- WuXi XDC
- Creative Biogene
- Bachem
- LGC Biosearch Technologies
- Sinopep
- Organix
- CD Formulation
- Hitgen
- Alnylam Pharmaceuticals, Inc.
- Amerigo Scientific
- BOCSCI Inc.
- Creative Biolabs
- BioSynthesis Inc
- Creative Peptide
- GenScript
- Suzhou Biosyntech
- Arrowhead Pharmaceuticals, Inc.
- Silence Therapeutics plc
- Dicerna Pharmaceuticals, Inc.
- Wave Life Sciences Ltd.
- Sirnaomics, Inc.
- Quark Pharmaceuticals, Inc.
- Others
GLOBAL SIRNA CONJUGATES MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2020 - 2033
- Rare Disease
- Oncology
- Chronic Disease
- Central Nervous System
- Cardiovascular
GLOBAL SIRNA CONJUGATES MARKET, BY DEVELOPMENT STAGE- MARKET ANALYSIS, 2020 - 2033
- Clinical Trials
- Phase I
- Phase II
- Phase III
- Commercial
- Preclinical
- In Vivo
- In Vitro
GLOBAL SIRNA CONJUGATES MARKET, BY CONJUGATE TYPE- MARKET ANALYSIS, 2020 - 2033
- Peptide
- Lipid Nanoparticle
- GalNAc
GLOBAL SIRNA CONJUGATES MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033
- Specialty Clinics
- Research Institutes
- Hospitals
GLOBAL SIRNA CONJUGATES MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. siRNA Conjugates Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. siRNA Conjugates Market Snippet by Therapeutic Area
2.1.2. siRNA Conjugates Market Snippet by Development Stage
2.1.3. siRNA Conjugates Market Snippet by Conjugate Type
2.1.4. siRNA Conjugates Market Snippet by End User
2.1.5. siRNA Conjugates Market Snippet by Country
2.1.6. siRNA Conjugates Market Snippet by Region
2.2. Competitive Insights
3. siRNA Conjugates Key Market Trends
3.1. siRNA Conjugates Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. siRNA Conjugates Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. siRNA Conjugates Market Opportunities
3.4. siRNA Conjugates Market Future Trends
4. siRNA Conjugates Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. siRNA Conjugates Market : Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. siRNA Conjugates Market Landscape
6.1. siRNA Conjugates Market Share Analysis, 2025
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. siRNA Conjugates Market – By Therapeutic Area
7.1. Overview
7.1.1. Segment Share Analysis, By Therapeutic Area, 2025 & 2033 (%)
7.1.2. Rare Disease
7.1.3. Oncology
7.1.4. Chronic Disease
7.1.5. Central Nervous System
7.1.6. Cardiovascular
8. siRNA Conjugates Market – By Development Stage
8.1. Overview
8.1.1. Segment Share Analysis, By Development Stage, 2025 & 2033 (%)
8.1.2. Clinical Trials
8.1.2.1. Phase I
8.1.2.2. Phase II
8.1.2.3. Phase III
8.1.3. Commercial
8.1.4. Preclinical
8.1.4.1. In Vivo
8.1.4.2. In Vitro
9. siRNA Conjugates Market – By Conjugate Type
9.1. Overview
9.1.1. Segment Share Analysis, By Conjugate Type, 2025 & 2033 (%)
9.1.2. Peptide
9.1.3. Lipid Nanoparticle
9.1.4. GalNAc
10. siRNA Conjugates Market – By End User
10.1. Overview
10.1.1. Segment Share Analysis, By Development Stage, 2025 & 2033 (%)
10.1.2. Specialty Clinics
10.1.3. Research Institutes
10.1.4. Hospitals
11. siRNA Conjugates Market – By Geography
11.1. Introduction
11.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
11.2. North America
11.2.1. Overview
11.2.2. siRNA Conjugates Key Manufacturers in North America
11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.2.4. North America Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.2.5. North America Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.2.6. North America Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.2.7. North America Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.2.8. U.S.
11.2.8.1. Overview
11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.2.8.3. U.S. Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.2.8.4. U.S. Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.2.8.5. U.S. Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.2.8.6. U.S. Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.2.9. Canada
11.2.9.1. Overview
11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.2.9.3. Canada Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.2.9.4. Canada Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.2.9.5. Canada Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.2.9.6. Canada Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3. Europe
11.3.1. Overview
11.3.2. siRNA Conjugates Key Manufacturers in Europe
11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.3.4. Europe Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.3.5. Europe Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.3.6. Europe Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.3.7. Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.8. Germany
11.3.8.1. Overview
11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.8.3. Germany Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.3.8.4. Germany Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.3.8.5. Germany Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.3.8.6. Germany Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.9. UK
11.3.9.1. Overview
11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.9.3. UK Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.3.9.4. UK Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.3.9.5. UK Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.3.9.6. UK Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.10. France
11.3.10.1. Overview
11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.10.3. France Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.3.10.4. France Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.3.10.5. France Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.3.10.6. France Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.11. Italy
11.3.11.1. Overview
11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.11.3. Italy Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.3.11.4. Italy Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.3.11.5. Italy Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.3.11.6. Italy Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.12. Spain
11.3.12.1. Overview
11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.12.3. Spain Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.3.12.4. Spain Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.3.12.5. Spain Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.3.12.6. Spain Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.13. The Netherlands
11.3.13.1. Overview
11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.13.3. The Netherlands Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.3.13.4. The Netherlands Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.3.13.5. The Netherlands Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.3.13.6. The Netherlands Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.14. Sweden
11.3.14.1. Overview
11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.14.3. Sweden Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.3.14.4. Sweden Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.3.14.5. Sweden Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.3.14.6. Sweden Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.15. Russia
11.3.15.1. Overview
11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.15.3. Russia Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.3.15.4. Russia Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.3.15.5. Russia Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.3.15.6. Russia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.16. Poland
11.3.16.1. Overview
11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.16.3. Poland Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.3.16.4. Poland Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.3.16.5. Poland Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.3.16.6. Poland Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.17. Denmark
11.3.17.1. Overview
11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.17.3. Poland Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.3.17.4. Denmark Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.3.17.5. Denmark Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.3.17.6. Denmark Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.18. Rest of Europe
11.3.18.1. Overview
11.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.18.3. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.3.18.4. Rest of the Europe Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.3.18.5. Rest of the Europe Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.3.18.6. Rest of the Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4. Asia Pacific (APAC)
11.4.1. Overview
11.4.2. siRNA Conjugates Key Manufacturers in Asia Pacific
11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.4.4. APAC Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.4.5. APAC Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.4.6. APAC Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.4.7. APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.8. China
11.4.8.1. Overview
11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.8.3. China Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.4.8.4. China Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.4.8.5. China Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.4.8.6. China Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.9. India
11.4.9.1. Overview
11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.9.3. India Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.4.9.4. India Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.4.9.5. India Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.4.9.6. India Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.10. Japan
11.4.10.1. Overview
11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.10.3. Japan Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.4.10.4. Japan Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.4.10.5. Japan Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.4.10.6. Japan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.11. South Korea
11.4.11.1. Overview
11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.11.3. South Korea Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.4.11.4. South Korea Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.4.11.5. South Korea Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.4.11.6. South Korea Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.12. Australia
11.4.12.1. Overview
11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.12.3. Australia Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.4.12.4. Australia Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.4.12.5. Australia Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.4.12.6. Australia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.13. Indonesia
11.4.13.1. Overview
11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.13.3. Indonesia Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.4.13.4. Indonesia Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.4.13.5. Indonesia Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.4.13.6. Indonesia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.14. Thailand
11.4.14.1. Overview
11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.14.3. Thailand Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.4.14.4. Thailand Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.4.14.5. Thailand Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.4.14.6. Thailand Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.15. Philippines
11.4.15.1. Overview
11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.15.3. Philippines Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.4.15.4. Philippines Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.4.15.5. Philippines Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.4.15.6. Philippines Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.16. Taiwan
11.4.16.1. Overview
11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.16.3. Taiwan Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.4.16.4. Taiwan Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.4.16.5. Taiwan Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.4.16.6. Taiwan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.17. Vietnam
11.4.17.1. Overview
11.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.17.3. Vietnam Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.4.17.4. Vietnam Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.4.17.5. Vietnam Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.4.17.6. Vietnam Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.18. Rest of APAC
11.4.18.1. Overview
11.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.18.3. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.4.18.4. Rest of APAC Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.4.18.5. Rest of APAC Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.4.18.6. Rest of APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.5. Latin America (LATAM)
11.5.1. Overview
11.5.2. siRNA Conjugates Key Manufacturers in Latin America
11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.5.4. LATAM Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.5.5. LATAM Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.5.6. LATAM Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.5.7. LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.5.8. Brazil
11.5.8.1. Overview
11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.8.3. Brazil Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.5.8.4. Brazil Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.5.8.5. Brazil Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.5.8.6. Brazil Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.5.9. Mexico
11.5.9.1. Overview
11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.9.3. Mexico Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.5.9.4. Mexico Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.5.9.5. Mexico Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.5.9.6. Mexico Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.5.10. Argentina
11.5.10.1. Overview
11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.10.3. Argentina Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.5.10.4. Argentina Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.5.10.5. Argentina Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.5.10.6. Argentina Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.5.11. Colombia
11.5.11.1. Overview
11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.11.3. Colombia Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.5.11.4. Colombia Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.5.11.5. Colombia Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.5.11.6. Colombia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.5.12. Rest of LATAM
11.5.12.1. Overview
11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.12.3. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.5.12.4. Rest of LATAM Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.5.12.5. Rest of LATAM Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.6. Middle East and Africa (MEA)
11.6.1. Overview
11.6.2. siRNA Conjugates Key Manufacturers in Middle East and Africa
11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.6.4. MEA Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.6.5. MEA Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.6.6. MEA Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.6.7. MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.6.8. Saudi Arabia
11.6.8.1. Overview
11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.8.3. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.6.8.4. Saudi Arabia Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.6.8.5. Saudi Arabia Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.6.9. United Arab Emirates
11.6.9.1. Overview
11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.9.3. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.6.9.4. United Arab Emirates Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.6.9.5. United Arab Emirates Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.6.10. Israel
11.6.10.1. Overview
11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.10.3. Israel Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.6.10.4. Israel Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.6.10.5. Israel Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.6.10.6. Israel Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.6.11. Turkey
11.6.11.1. Overview
11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.11.3. Turkey Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.6.11.4. Turkey Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.6.11.5. Turkey Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.6.11.6. Turkey Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.6.12. Algeria
11.6.12.1. Overview
11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.12.3. Algeria Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.6.12.4. Algeria Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.6.12.5. Algeria Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.6.12.6. Algeria Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.6.13. Egypt
11.6.13.1. Overview
11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.13.3. Egypt Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.6.13.4. Egypt Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.6.13.5. Egypt Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.6.13.6. Egypt Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.6.14. Iran
11.6.14.1. Overview
11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.14.3. Iran Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.6.14.4. Iran Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.6.14.5. Iran Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.6.14.6. Iran Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.6.15. Qatar
11.6.15.1. Overview
11.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.15.3. Qatar Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.6.15.4. Qatar Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.6.15.5. Qatar Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.6.15.6. Qatar Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.6.16. Rest of MEA
11.6.16.1. Overview
11.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.16.3. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.6.16.4. Rest of MEA Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
11.6.16.5. Rest of MEA Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
11.6.16.6. Rest of MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12. Key Vendor Analysis- siRNA Conjugates Industry
12.1. Competitive Benchmarking
12.1.1. Competitive Dashboard
12.1.2. Competitive Positioning
12.2. Company Profiles
12.2.1. WuXi XDC
12.2.2. Creative Biogene
12.2.3. Bachem
12.2.4. LGC Biosearch Technologies
12.2.5. Sinopep
12.2.6. Organix
12.2.7. CD Formulation
12.2.8. Hitgen
12.2.9. Alnylam Pharmaceuticals, Inc.
12.2.10. Amerigo Scientific
12.2.11. BOCSCI Inc.
12.2.12. Creative Biolabs
12.2.13. BioSynthesis Inc
12.2.14. Creative Peptide
12.2.15. GenScript
12.2.16. Suzhou Biosyntech
12.2.17. Arrowhead Pharmaceuticals, Inc.
12.2.18. Silence Therapeutics plc
12.2.19. Dicerna Pharmaceuticals, Inc.
12.2.20. Wave Life Sciences Ltd.
12.2.21. Sirnaomics, Inc.
12.2.22. Quark Pharmaceuticals, Inc.
12.2.23. Others
13. 360 Degree AnalystView
14. Appendix
14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL SIRNA CONJUGATES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- WuXi XDC
- Creative Biogene
- Bachem
- LGC Biosearch Technologies
- Sinopep
- Organix
- CD Formulation
- Hitgen
- Alnylam Pharmaceuticals, Inc.
- Amerigo Scientific
- BOCSCI Inc.
- Creative Biolabs
- BioSynthesis Inc
- Creative Peptide
- GenScript
- Suzhou Biosyntech
- Arrowhead Pharmaceuticals, Inc.
- Silence Therapeutics plc
- Dicerna Pharmaceuticals, Inc.
- Wave Life Sciences Ltd.
- Sirnaomics, Inc.
- Quark Pharmaceuticals, Inc.
- Others
GLOBAL SIRNA CONJUGATES MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2020 - 2033
- Rare Disease
- Oncology
- Chronic Disease
- Central Nervous System
- Cardiovascular
GLOBAL SIRNA CONJUGATES MARKET, BY DEVELOPMENT STAGE- MARKET ANALYSIS, 2020 - 2033
- Clinical Trials
- Phase I
- Phase II
- Phase III
- Commercial
- Preclinical
- In Vivo
- In Vitro
GLOBAL SIRNA CONJUGATES MARKET, BY CONJUGATE TYPE- MARKET ANALYSIS, 2020 - 2033
- Peptide
- Lipid Nanoparticle
- GalNAc
GLOBAL SIRNA CONJUGATES MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033
- Specialty Clinics
- Research Institutes
- Hospitals
GLOBAL SIRNA CONJUGATES MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
